Press Releases

October 03, 2019 Devonian Health Group Obtains Cannabis Research License from Health Canada

September 04, 2019 Devonian Health Group Announces the Formation of a Clinical Dermatology Advisory Board with mandate to assist in the development of Cannabinoids-based pharmaceutical products

August 29, 2019 Devonian Health Group announces the publication of positive results of the Purgenesis® Anti-aging Care clinical study in the Journal of Cosmetic Dermatology

August 21, 2019 DEVONIAN ANNOUNCES THE CLOSING OF A $315,000 PRIVATE PLACEMENT AND AN ADDITIONAL LOAN OF $500,000

July 23, 2019 Dr George G. Zhanel joins Devonian’s Cannabinoids Scientific Advisory board

June 05, 2019 Devonian Announces the Filing of a New Patent Application related to use of Thylakoids as delivery system for Cannabinoïds and other Liposoluble Molecules

June 03, 2019 Devonian signs a Binding Letter of Intent with Histapharm Inc. to extract and manufacture their proprietary botanical pharmaceutical product and to enter into a Strategic Partnership for the development of New Products

April 10, 2019 Devonian Health Group Announces the Formation of a Scientific Advisory Board with mandate to assist in the development of Cannabinoïds-based pharmaceutical products

April 08, 2019 Devonian Health Group announces the publication of results of in vitro assessment of the antioxidant and UV protection properties of thylakoid extracts in Journal of Cosmetic Dermatology

April 02, 2019 Devonian Healthcare Group Reports Key Financial Results for Quarter Ended January 31, 2019

April 01, 2019 Devonian Health Group issues Securities In Interest Settlement Due To Debenture Holders and grants options

January 31, 2019 Devonian Announces voting results of the Annual General and Special Meeting

January 29, 2019 Devonian Health Group Provides an update on its Phase 2 Clinical Study in Atopic Dermatitis and Announces plans for the first photoprotection product issued from its Cosmeceutical R&D program

January 23, 2019 Devonian Health Group Announces the refinancing of the loan on its pharmaceutical facility